Known Side Effects from Combination Studies
Lurbinectedin (Zepzelca), approved for small cell lung cancer, has been tested with immunotherapies like pembrolizumab (Keytruda) in trials for extensive-stage disease. The most common side effects in these combinations include myelosuppression (neutropenia, thrombocytopenia, anemia), fatigue, nausea, decreased appetite, and dyspnea. These overlap with individual drug toxicities but can intensify.[1][2]
How Toxicity Differs from Monotherapy
In the phase II LUC2021 trial (NCT04865737), lurbinectedin plus pembrolizumab showed grade 3/4 adverse events in 69% of patients, mainly hematologic (neutropenia 38%, anemia 16%). This is comparable to immunotherapy alone but higher for cytopenias due to lurbinectedin's mechanism. No unexpected toxicities emerged, and discontinuation rates stayed low at 12%.[2][3]
Specific Risks with PD-1 Inhibitors
Combining with PD-1/PD-L1 blockers like pembrolizumab or atezolizumab raises immune-related adverse events (irAEs) such as pneumonitis (5-10% incidence), rash, and hypothyroidism. Lurbinectedin may exacerbate transaminitis or colitis when overlapping with checkpoint inhibitors. Prophylactic G-CSF reduced severe neutropenia in trials.[1][4]
Patient Management and Monitoring
Dose reductions occurred in 40-50% of combo patients, mainly for cytopenias. Liver function tests, complete blood counts, and irAE surveillance (e.g., thyroid, pulmonary imaging) are standard. No fatal toxicities linked directly to the combo were reported in key studies.[2]
Ongoing Trials and Data Gaps
Phase III trials like KEYNOTE-826 (NCT04866358) and IMforte (NCT04796054) continue evaluating lurbinectedin-immunotherapy combos in SCLC and other cancers. Long-term data on rare events like cardiac toxicity or secondary malignancies is limited.[3]
[1]: FDA Label for Zepzelca (lurbinectedin), 2023 update. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213069s000lbl.pdf
[2]: Trigo et al., *Lung Cancer* 2023; phase II results. https://pubmed.ncbi.nlm.nih.gov/36958288/
[3]: ClinicalTrials.gov summaries for NCT04865737 and NCT04866358. https://clinicaltrials.gov
[4]: ESMO Guidelines on SCLC management, 2024. https://www.esmo.org/guidelines